Pre-Open Stock Movers 02/22: (MTOR) (VEV) (HMHC) Higher; (FIXX) (KPTI) (YNDX) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Macy's (M) PT Lowered to $40 at Jefferies
February 23, 2022 7:44 AM ESTJefferies analyst Stephanie Wissink lowered the price target on Macy's (NYSE: M) to $40.00 (from $45.00) while maintaining a Buy rating following results.
The analyst commented, "M beat Q4, guided FY22 above the Street, and issued 3YR targets of +LSD% sales growth and LDD% EBITDA... More
Karyopharm Therapeutics (KPTI) Wild Ride Occurring as M&A Speculation Proved Wrong Amid Executive Departure - RBC
February 22, 2022 12:40 PM ESTRBC Capital analyst Brian Abrahams weighed in on Karyopharm Therapeutics (NASDAQ: KPTI) amid the recent turbulence in the stock, including the 20% up move on Friday on the conference cancellation, which triggered M&A speculation, and today's 31% downdraft on the departure of CMO Dr. Jatin... More
Morgan Stanley Reiterates Equalweight Rating on Karyopharm Therapeutics (KPTI), 'lack of potential takeout news likely to disappoint'
February 22, 2022 10:33 AM ESTMorgan Stanley analyst Michael Ulz reiterated an Equalweight rating and $10.00 price target on Karyopharm Therapeutics (NASDAQ: KPTI).
The analyst comments "CMO departure surprising, but lack of potential takeout news likely to disappoint. This morning, Karyopharm announced several changes to the clinical leadership team. Most notable, Jatin Shah, EVP and CMO for the past 5 years, is leaving to pursue other opportunities... More
